重复鞘内注射间充质干细胞治疗肌萎缩侧索硬化
这项2期随机对照试验将64例肌萎缩侧索硬化(ALS)患者按1:1随机分配为两组:单用利鲁唑的对照组(n=31)与利鲁唑联合2次自体骨髓来源间充质干细胞(BM-MSC)鞘内注射的MSC组(n=33)。结果显示,未出现与治疗相关的严重不良事件,两组安全性无组间差异;MSC组在注射后4个月和6个月的ALS功能评定量表修订版(ALSFRS-R)评分相对基线的变化小于对照组(4个月:2.98,95%CI 1.48-4.47,p<0.001;6个月:3.38,95%CI 1.23-5.54,p=0.003),且MSC组促炎细胞因子降低、抗炎细胞因子升高;两组长期生存无显著差异。
要点
- 2期随机对照试验显示,2次鞘内注射BM-MSC未出现与治疗相关的严重不良事件,两组安全性无组间差异。
- MSC组注射后4个月和6个月的ALSFRS-R评分相对基线的变化小于对照组(4个月:2.98,95%CI 1.48-4.47,p<0.001;6个月:3.38,95%CI 1.23-5.54,p=0.003)。
- 两组长期生存无显著差异,作者认为仍需开展更大规模的双盲3期试验评估长期疗效与安全性。
核心结论
- 重复鞘内注射BM-MSC在ALS患者中显示出可能持续至少6个月的临床获益,且具有安全性;作者认为其可能的作用机制是BM-MSC介导了从促炎状态向抗炎状态的转换。
- 作者认为仍需开展进一步随机、双盲、大规模3期临床试验并增加BM-MSC治疗次数,以评估长期疗效与安全性。
研究设计与样本
- 2期随机对照试验(NCT01363401),64例ALS参与者按1:1随机分配接受单用利鲁唑(对照组,n=31)或联合2次BM-MSC注射(MSC组,n=33)。
- 安全性依据不良事件的发生情况评估;主要疗效结局为注射后4个月和6个月时ALSFRS-R评分相对基线的变化。
- 事后分析包括脑脊液生物标志物检测和长期生存分析。
主要发现
- 安全性评价显示两组无组间差异,且未出现与治疗相关的严重不良事件。
- MSC组ALSFRS-R评分相对基线的平均变化在注射后4个月和6个月时均小于对照组(4个月:2.98,95%CI 1.48-4.47,p<0.001;6个月:3.38,95%CI 1.23-5.54,p=0.003)。
- MSC组促炎细胞因子降低、抗炎细胞因子升高;在应答良好者中,转化生长因子β1与单核细胞趋化蛋白-1呈显著负相关。
- 两组长期生存无显著差异。
局限性
- 作者指出,仍需开展进一步随机、双盲、大规模3期临床试验并增加BM-MSC治疗次数,以评估长期疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the safety and efficacy of 2 repeated intrathecal injections of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in amyotrophic lateral sclerosis (ALS). METHODS: In a phase 2 randomized controlled trial (NCT01363401), 64 participants with ALS were randomly assigned treatments (1:1) of riluzole alone (control group, n = 31) or combined with 2 BM-MSC injections (MSC group, n = 33). Safety was assessed based on the occurrence of adverse events. The primary efficacy outcome was changes in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score from baseline to 4 and 6 months postinjection. Post hoc analysis includes investigation of cerebrospinal fluid biomarkers and long-term survival analysis. RESULTS: Safety rating showed no groupwise difference with absence of serious treatment-related adverse events. Mean changes in ALSFRS-R scores from baseline to 4 and 6 months postinjection were reduced in the MSC group compared with the control group (4 months: 2.98, 95% confidence interval [CI] = 1.48-4.47, p < 0.001; 6 months: 3.38, 95% CI = 1.23-5.54, p = 0.003). The MSC group showed decreased proinflammatory and increased anti-inflammatory cytokines. In good responders, transforming growth factor β1 significantly showed inverse correlation with monocyte chemoattractant protein-1. There was no significant difference in long-term survival between groups. INTERPRETATION: Repeated intrathecal injections of BM-MSCs demonstrated a possible clinical benefit lasting at least 6 months, with safety, in ALS patients. A plausible action mechanism is that BM-MSCs mediate switching from pro- to anti-inflammatory conditions. A future randomized, double-blind, large-scale phase 3 clinical trial with additional BM-MSC treatments is required to evaluate long-term efficacy and safety. Ann Neurol 2018;84:361-373.
引用
- Oh KW, Noh MY, Kwon MS, et al. Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis. Ann Neurol. 2018. PMID: 30048006. doi:10.1002/ana.25302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。